重症患者外周静脉导管相关静脉炎的危险因素:日本23个ICU中3429根导管的分析
该研究为AMOR-VENUS前瞻性多中心队列的二次分析,纳入日本23个ICU中年龄≥18岁、入ICU后新置入外周静脉导管的连续患者,共1359例患者、3429根导管,中位留置时间46.2小时。静脉炎发生率为9.1%(3.5例/100导管日)。多因素分析显示,仅静脉给药种类与静脉炎风险独立相关:尼古地平(HR 1.85)、去甲肾上腺素(HR 2.42)、胺碘酮(HR 3.67)和左乙拉西坦(HR 5.65)增加风险;ICU标准化给药措施(HR 0.35)、BMI≥30(HR 0.43)、医生因护士参考而置管(HR 0.55)、上臂置入部位(HR 0.52)及硝酸甘油(HR 0.22)与风险降低相关。作者认为需在ICU中采取合适的装置选择或照护模式。
要点
- 在23个日本ICU的3429根外周静脉导管中,静脉炎发生率为9.1%(95%CI 8.2-10.1%),即3.5例/100导管日,中位留置时间46.2小时(95%CI 21.3-82.9)。
- 经外周静脉给予左乙拉西坦(HR 5.65;95%CI 2.80-11.4)、胺碘酮(HR 3.67;95%CI 1.75-7.71)、去甲肾上腺素(HR 2.42;95%CI 1.40-4.20)和尼古地平(HR 1.85;95%CI 1.29-2.66)与静脉炎风险升高独立相关。
- ICU内标准化给药措施与静脉炎风险降低独立相关(HR 0.35;95%CI 0.17-0.76),提示给药流程标准化可能降低风险。
- BMI≥30(HR 0.43;95%CI 0.20-0.95)、医生因护士参考而置管(HR 0.55;95%CI 0.32-0.94)和上臂置入部位(以 forearm 为参照,HR 0.52;95%CI 0.32-0.85)与静脉炎风险降低相关。
- 硝酸甘油经外周静脉给药与静脉炎风险降低相关(HR 0.22;95%CI 0.05-0.92)。
适用人群与场景
- 日本23个ICU中年龄≥18岁、入住ICU后新置入外周静脉导管的连续患者;共1359例患者、3429根导管纳入分析。
研究设计与关键结果
- 研究设计:AMOR-VENUS前瞻性多中心队列研究的二次分析,涉及日本23个ICU;共2741例连续患者接受资格筛选,最终1359例患者和3429根外周静脉导管纳入分析。
- 静脉炎发生率:9.1%(95%CI 8.2-10.1%)的导管发生静脉炎,即3.5例/100导管日;中位留置时间46.2小时(95%CI 21.3-82.9)。
- 多因素分析(边际Cox回归)显示,唯一增加静脉炎风险的独立因素为静脉给药;共分析26种药物,其中4种与静脉炎风险升高相关:尼古地平(HR 1.85;95%CI 1.29-2.66)、去甲肾上腺素(HR 2.42;95%CI 1.40-4.20)、胺碘酮(HR 3.67;95%CI 1.75-7.71)、左乙拉西坦(HR 5.65;95%CI 2.80-11.4)。
- 与静脉炎风险降低独立相关的因素:ICU标准化给药措施(HR 0.35;95%CI 0.17-0.76)、30≤BMI(HR 0.43;95%CI 0.20-0.95)、医生因护士参考而置管(HR 0.55;95%CI 0.32-0.94)、上臂置入部位(以 forearm 为参照,HR 0.52;95%CI 0.32-0.85)。
- 硝酸甘油经外周静脉给药与静脉炎风险降低相关(HR 0.22;95%CI 0.05-0.92)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究的二次分析(AMOR-VENUS研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重症患者外周静脉导管相关静脉炎涉及机构、患者、导管和药物等多方面因素,提示ICU中需进行合适的装置选择或照护模式。
指南或共识出处
- AMOR-VENUS研究;试验注册号UMIN000028019(日本临床试验注册库,注册日期2017年7月1日)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Phlebitis is an important complication occurring in patients with peripheral intravascular catheters (PIVCs). The risk factors for phlebitis in the intensive care unit (ICU) was examined.
METHODS: A secondary analysis of a prospective multicenter cohort study was conducted, involving 23 ICUs in Japan-the AMOR-VENUS study. Consecutive patients aged ≥ 18 years admitted to the ICU with newly inserted PIVCs after ICU admission were enrolled. Characteristics of the ICU, patients, PIVCs, and the drugs administered via PIVCs were recorded. A marginal Cox regression model was used to identify the risk factors associated with phlebitis.
RESULTS: A total of 2741 consecutive patients from 23 ICUs were reviewed for eligibility, resulting in 1359 patients and 3429 PIVCs being included in the analysis population. The median dwell time was 46.2 h (95% confidence interval [CI], 21.3-82.9). Phlebitis occurred in 9.1% (95% CI, 8.2-10.1%) of catheters (3.5 cases/100 catheter days). The multivariate analysis revealed that the only factors that increased the risk of developing phlebitis were drugs administered intravenously. This study included 26 drugs, and 4 were associated with increased phlebitis: nicardipine (HR, 1.85; 95% CI, 1.29-2.66), noradrenaline (HR, 2.42; 95% CI, 1.40-4.20), amiodarone (HR, 3.67; 95% CI, 1.75-7.71) and levetiracetam (HR, 5.65; 95% CI, 2.80-11.4). Alternatively, factors significantly associated with a reduced risk of phlebitis were: standardized drug administration measures in the ICU (HR, 0.35; 95% CI, 0.17-0.76), 30≤ BMI (HR, 0.43; 95% CI, 0.20-0.95), catheter inserted by a doctor as nurse reference (HR, 0.55; 95% CI, 0.32-0.94), and upper arm insertion site as forearm reference (HR, 0.52; 95% CI, 0.32-0.85). The nitroglycerin was associated with a reduced phlebitis risk (HR, 0.22; 95% CI, 0.05-0.92).
CONCLUSION: Various factors are involved in the development of phlebitis caused by PIVCs in critically ill patients, including institutional, patient, catheter, and drug-induced factors, indicating the need for appropriate device selection or models of care in the ICU.
TRIAL REGISTRATION: UMIN-CTR, the Japanese clinical trial registry (registration number: UMIN000028019, July 1, 2017).
参考来源
- Yasuda H, Rickard CM, Marsh N, et al. Risk factors for peripheral intravascular catheter-related phlebitis in critically ill patients: analysis of 3429 catheters from 23 Japanese intensive care units. Ann Intensive Care. 2022. PMID: 35394571. doi:10.1186/s13613-022-01009-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。